Allspring Global Investments Holdings LLC Raises Stake in Repligen Corporation $RGEN

Allspring Global Investments Holdings LLC increased its holdings in Repligen Corporation (NASDAQ:RGEN) by 2.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 311,175 shares of the biotechnology company’s stock after buying an additional 7,430 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.55% of Repligen worth $51,142,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Iron Triangle Partners LP purchased a new position in shares of Repligen during the third quarter worth $36,091,000. Delta Investment Management LLC purchased a new stake in Repligen in the third quarter valued at $6,779,000. Congress Asset Management Co. boosted its holdings in Repligen by 43.4% in the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock valued at $29,219,000 after purchasing an additional 66,142 shares during the last quarter. Cinctive Capital Management LP acquired a new stake in Repligen during the 3rd quarter worth about $3,398,000. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Repligen during the 3rd quarter valued at about $2,807,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

NASDAQ:RGEN opened at $118.32 on Thursday. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77. The stock’s 50-day moving average price is $132.26 and its 200-day moving average price is $146.45. The stock has a market capitalization of $6.66 billion, a PE ratio of 139.20, a price-to-earnings-growth ratio of 2.30 and a beta of 1.19.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.Repligen’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, equities analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of several analyst reports. UBS Group decreased their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays decreased their price target on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Wells Fargo & Company dropped their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, HC Wainwright lifted their target price on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $176.92.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.